Sanofi puts brakes on phase 3 trials of myasthenia gravis candidate tolebrutinib

Feb. 03, 2023 2:15 PM ETSanofi (SNY)AZNBy: Jonathan Block, SA News Editor

Blue glass European building architecture with Sanofi logo Berlin


  • Sanofi (NASDAQ:SNY) has put on hold all phase 3 studies of its BTK inhibitor tolebrutinib for myasthenia gravis ("MG").
  • In June 2022, the US FDA placed a partial clinical hold on the candidate for MG and multiple sclerosis after liver

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.